BILCAP results show chemo improves survival

AMMF welcomes the encouraging results announced today by Cancer Research UK following the BILCAP trial into the use of the chemotherapy drug Capecitabine (Xeloda) for bile duct cancer (cholangiocarcinoma) patients following surgery. The three year survival improved by almost a quarter (23 per cent) in patients who were given Capecitabine, and the average survival was increased to 53 months from 36 months...

Read More

AMMF’s Cholangiocarcinoma Conference 2017

AMMF will bring together scientists, researchers, medics and patients from around the world at its conference dedicated exclusively to cholangiocarcinoma, on 11 May, 2017 at the Radisson Blu Hotel, Stansted Airport, Essex. With the date just a couple of weeks away, a press release has now been distributed sharing information on what promises to be a very interesting and thought provoking day ... &...

Read More

AMMF CEO interviewed by Pan European Networks journal …

AMMF CEO Helen Morement was recently interviewed by the Pan European Networks journal and, in a 3-page article, discusses some of the known and suspected causes of cholangiocarcinoma, why diagnosis remains so difficult, current and future treatment options, as well as the wider work of the charity throughout the UK and beyond. With the article published just ahead of the second World Cholangiocarcinoma Day...

Read More

AMMF’s brochure – updated …

AMMF’s brochure has been updated and is now available in two versions - a printed version and a download version available from our website. Simple and straightforward, this 6-page brochure contains information on AMMF and its aims, and provides details on cholangiocarcinoma in an easy to understand way. Everyone can use the brochure to raise the awareness of cholangiocarcinoma and of AMMF - make su...

Read More

ESMO Guidelines – SIRT an option for iCC

The new ESMO Biliary Cancer Guidelines indicate Selective Internal Radiation Therapy (SIRT) with Y-90 Microspheres as an option for post-chemotherapy treatment of intrahepatic cholangiocarcinoma (iCCA). The new ESMO1 guidelines on biliary cancers2 were published in September 2016 as a supplement to the Annals of Oncology. Their lead author, Professor Juan Valle of the Christie NHS Foundation Trust, Univers...

Read More

PCI Biotech CCA study selected for presentation

Oslo: October 17, 2016 – PCI Biotech, the cancer focused biopharmaceutical company, announced that an abstract with results from their Phase I cholangiocarcinoma study had been selected for oral presentation as late-breaking news at this week's United European Gastroenterology (UEG) conference in Vienna, Austria. The results will be presented by Dr. Alexander Dechêne, University Hospital Essen, Germany,...

Read More

Ambling around the world!

Thank you to everyone who took part in the first ever ‘Amble for AMMF’ on Sunday 4th September, 2016. This event caught the imagination of hundreds of people who joined in and ambled in many parts of the world - across the UK, in Ireland, the USA, France and even Eastern Siberia! Through the generosity of AMMF's Amblers, an astounding £10,000 was raised which will be an enormous help with the ch...

Read More

Edinburgh study identifies CC trigger …

AMMF is delighted to see that the positive research findings of work the charity has been co-funding at the University of Edinburgh have been published in the Proceedings of the National Academy of Sciences. The Edinburgh team have identified a molecule that is a key driver in the development of bile duct cancer (cholangiocarcinoma). They have shown that this molecule - Notch 3 - triggers a pathway o...

Read More

AMMF’s research awards – now in excess of £0.5m

Since AMMF was founded in 2002, one of the charity’s major objectives has been to support specialised research teams in their work to find the causes, methods of earlier diagnosis and effective treatments for cholangiocarcinoma (CC). Thanks to the unstinting and generous help of its fundraisers and donors, AMMF has awarded in excess of £0.5m (half a million pounds sterling) in grants to support cholangi...

Read More

PCI Biotech trial report

A cancer focused biopharmaceutical company based in Norway, PCI Biotech, have recently reported an update on their phase I/II study in inoperable bile duct cancer patients. “The phase I part of the study has been completed with good tolerability and promising early signs of efficacy. The independent evaluation of the radiology data at six months from patients treated in cohort III and the expanded ...

Read More